YGEN.L Regulatory News (YGEN)

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

Opening of New Facilities and Corporate HQ

Manchester, UK - 28 November 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the official opening of its newly integrated facilities and corporate HQ at Citylabs 1.0, in the centre of Manchester's genomics campus, and continued expansion with a planned further increase in headcount at the Company's UK headquarters.

The establishment of the new Company head office at Citylabs 1.0, Nelson Street, Manchester, M13 9NQ, in the centre of Manchester's genomics campus, is part of the ongoing integration of the Elucigene acquisition which completed in April 2019. Citylabs is based on a joint venture partnership between Manchester Science Partnerships, the UK's leading science and technology park operator, and Manchester University NHS Foundation Trust, the UK's largest NHS provider Trust, and is the only development of its kind in the UK. The Citylabs campus, currently undergoing a £95m expansion, is surrounded by Manchester's leading hospitals and makes it part of Europe's largest clinical-academic campus.

Following the acquisition of Elucigene, all departments are being combined into a single management structure and manufacturing concentrated onto the one site and the new facility is already generating a strong cultural alignment across the enlarged Group. Plans for process, systems and regulatory harmonisation are well advanced and will be completed by the end of the financial year in March 2020.

Yourgene Health currently employs 125 staff around the world, with 89 staff now based at the enlarged UK headquarters in Manchester. The Company has aspirations to grow staff numbers to support the business growth anticipated over the next few years. The Company is currently recruiting new staff in Manchester and has opportunities for talented individuals with relevant scientific backgrounds and commercial experience: https://www.yourgene-health.com/contact-us/recruitment

Lyn Rees, CEO of Yourgene Health plc, said: "I am delighted at the progress we've made to integrate the Elucigene acquisition, and the opening of our new facilities and HQ at Citylabs, in the heart of Manchester's exciting genomics hub, marks a new stage of growth for our business. Together we have cultivated a dynamic fast-paced culture offering a great opportunity to work with class leading products and be part of developing and commercialising the next generation of products to improve patient health globally. Citylabs provides us with world-class facilities to operate from and a vibrant place to work for our team."

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.